Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Rash & Diarrhea Prophylaxis With Capivasertib
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Single Dose of BL0175 in Postmenopausal Women
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Status
- RECRUITING
- Phase
- PHASE3
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
- Status
- RECRUITING
- Phase
- PHASE2